Origin

Derived from erythropoietin (EPO), the hormone that drives red blood cell production. EPO's neuroprotective, anti-inflammatory, and nerve-repair effects run through a separate receptor complex (the innate repair receptor) from the one that stimulates red blood cells. ARA-290 was engineered to hit only the repair pathway, giving EPO-like tissue protection without raising red blood cell count or blood viscosity.

Mechanism

Binds the innate repair receptor, distinct from the classical EPO receptor, triggering anti-inflammatory and cytoprotective signaling in nerve and vascular tissue. Trials have shown it increases corneal small-nerve-fiber density, a direct, measurable marker of nerve regeneration.

Research summary

Evidence

Multiple placebo-controlled human trials exist. A double-blind trial in sarcoidosis patients with small fiber neuropathy (4 mg subcutaneous daily for 28 days) showed symptom improvement and increased corneal nerve fiber density versus placebo. Separate trials in type 2 diabetes patients with neuropathic symptoms showed improved metabolic control and symptom scores, with dose-ranging work across 1 mg, 4 mg, and 8 mg groups. It's one of the better-studied compounds in peptide communities, with real dose-response human data, a rarity here.

Evidence tier: Investigational (trialed) — see the methodology note for how this is assessed.

Citations

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain — Culver et al. 2017
ARA 290 for treatment of small fiber neuropathy in sarcoidosis — van Velzen et al. 2014
The erythropoietin-derived peptide ARA290 reverses mechanical allodynia in the neuritis model — Pulman et al. 2012
Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy — Brines et al. 2018

Reported benefits

Reduced neuropathic pain (burning, tingling, numbness from small fiber neuropathy)
Reported benefit for some autonomic nervous system symptoms (dysautonomia) in community anecdotes, though this indication is not clinically validated
Interest from the EDS/HSD community for small-fiber neuropathy that often accompanies connective tissue disorders

Dosing protocols reported in the literature & community

These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.

Reported dosing protocols
Route	Reported protocol
Subcutaneous injection	Clinical trial dosing used 4 mg once daily for 28 days as the primary studied protocol; other trial arms used 1 mg and 8 mg daily. There is no established chronic/maintenance dosing outside trial contexts, and self-experimenters generally try to mirror the 4 mg daily trial protocol for a similar duration.

Side effects

Generally well tolerated in trials with no major red flags reported
Does not raise red blood cell count or blood pressure the way EPO itself can — this was the whole design goal and trial data supports it

Safety notes

Community & reddit notes (anecdotal — not clinical evidence)

Less mainstream than BPC-157/TB-500, but draws strong interest from people with small fiber neuropathy, POTS/dysautonomia, and EDS/HSD, where standard treatment is mostly symptom management rather than repair. Cost and sourcing difficulty temper enthusiasm, and anecdotal reports of benefit are sparser than for the popular healing peptides.

Mixing compatibility

Pulled from a community-charted mixing-compatibility reference (anecdotal, clinic-use, and community-reported signals) — not a safety guarantee. Verify independently before combining anything.